Washington / Sydney / Amsterdam / Nantong / Melbourne / London / /
Company
OPERATING AND FINANCIAL REVIEW Benitec / Coms PLC / Page 8 Benitec Biopharma Ltd / Page 4 Benitec Biopharma Ltd / RNAi / EPO / uniQure BV / Genentech / NSW 2041 Share Registry Computershare Investor Services Pty Limited / Listed Companies / Clinical Trials Group / Pharminox Limited / Bankers Trust / ITC Limited / AMD / Mesoblast Limited / Listed Companies Stemline Therapeutics Inc. / Alchemia Limited / None Benitec Biopharma Ltd / Asia Pacific Emerging Company / Stemline Therapeutics Inc. / Genable Technologies Ltd / JP Morgan / FASTS / Leaf Energy Limited / Alexza Pharmaceuticals Inc. / NSW 2000 Bankers Westpac Banking Corporation / Regen BioPharma Inc / Tissue Therapies Limited. / Listed Companies Medistem Inc. / Newstar Ventures Ltd. / Epirus Biopharmaceuticals / Forward Pharma A/S / Revivicor Inc. / Listed Companies Ark Therapeutics Group plc / CORPORATE INFORMATION Corporate Structure Benitec Biopharma Limited / Syngenta International AG / ImpediMed Ltd / Benitec Biopharma Ltd / Education Australia Limited. / Datamonitor / Medistem Inc. / Ark Therapeutics Group plc / Biomer Technology Limited / Kellogg / Genetic Technologies Limited / Genera Biosystems Limited / Arana Therapeutics Ltd. / Deutsche Bank / NSW 2041 Australia Auditors Grant Thornton Audit Pty Ltd / Healthlinx Ltd. / Principal Activities Benitec / Domantis Inc. / Listed Companies ALS Ltd / Cephalon & GSK / Teva Pharmaceuticals / Calimmune Inc. / Page 2 Benitec Biopharma Ltd / Strawman Limited / Cephalon Inc. / Age-Related Macular Degeneration Page 6 Benitec Biopharma Ltd / Calzada Ltd. / NZI / BASF SE / Selecting Synteract Inc. / Teva Pharmaceutical Industries / Eastman Kodak Company / Progen Pharmaceuticals Ltd. / Polynoma LLC / Australian Securities Exchange Limited / Tacere Therapeutics / IDP Education Pty Ltd / ScienceMedia Inc. / Xceed Capital Limited. / Cryosite / BACK COVER BENITEC BIOPHARMA LIMITED / /
Continent
Europe / /
Country
United Kingdom / China / Italy / Spain / France / Japan / Australia / Germany / United States / /
Currency
USD / GBP / / /
Event
M&A / FDA Phase / Product Issues / Funding / Business Partnership / Company Listing Change / Employment Change / /
Facility
Stanford University / St Vincent’s Hospital / University of London / University of California / Hope Cancer Centre / Wollongong University / Queensland University of Technology / Chiplin’s Pharmacy / University of London Wet-AMD*** Acquired / University of New South Wales / Northwestern University / University of Massachusetts / University of Nottingham / Cornell University / University of NSW / Pipeline Benitec / Children’s Cancer Institute / /
IndustryTerm
treatment of this disease / preclinical asset using ddRNAi technology / Lung Cancer treatment / healthcare industry / healthcare/biotech sector / treatment for HCV / therapy for Hepatitis B / therapies for the treatment of life threatening diseases / biotechnology / therapeutic technology / gene therapy product / ddRNAi technology / pain product / Hepatitis C therapy / large pharmaceutical / finance / gene therapy technology space / investment banking / ddRNAi‐based gene silencing technology / clinical trial protocol / technology lawyers / treatment for Huntington’s disease / pharmaceutical / ddRNAi gene silencing technology / antibody developer / biotechnology industry / /
MedicalCondition
ALS / Macular Degeneration / inflammatory mediators / lung tumours / non-small cell lung cancer / orphan disease / hepatocellular carcinoma / diseases / inflammatory disease / tumours / Hepatitis B. Infection / rare genetic diseases / Huntington’s Disease / Hepatitis C / company’s considerable Hepatitis C / common cancer / disease / human lung cancer / eye disease retinitis pigmentosa / pain / Non Small Cell Lung Cancer / Lung cancer / neurological diseases / Chemotherapy-resistant lung cancer / HBV / retinitis pigmentosa / cirrhosis / Hepatitis B / melanoma / incurable diseases / HBV-related liver failure / Breast Cancer / cancer / NSCLC / Chronic / HCV / AIDS / chronic carriers / oculopharyngeal muscular dystrophy / high profile diseases / terminal cancer / inflammatory mediator VEGF / Cancer Related Chronic / autoimmune diseases / cancers / uniQure Discovery Preclinical *Non-small cell lung cancer / These diseases / chemotherapy-resistant cancers **Oculopharyngeal Muscular Dystrophy / infectious diseases / human disease / /
MedicalTreatment
chemotherapy / gene therapy / organ transplants / /
Federal Drug Administration / World Health Organization / Children’s Cancer Institute Australia / Cornell University / Council of Royal Holloway / St Vincent’s Hospital / University of London Wet-AMD*** Acquired / Children’s Medical Research Foundation / University of London / University of Massachusetts / New Zealand Society for Cell and Developmental Biology / Duke Clinical Research Unit / Northwestern University / Carnegie Institution / Wollongong University / NIH’s DNA Recombinant Advisory Committee / Queensland University of Technology / Board of Directors of Stemline Therapeutics / Board of FASTS / European Union / Centre for Immunology / University of California / San Diego / Board of Directors of TetraLogic Pharmaceuticals / National Institute of Health / School of Management / American Association for the Study of Liver Disorders / Stanford School of Medicine / Hope Cancer Centre / University of New South Wales / University of NSW / Recombinant DNA Advisory Committee / Congress / Graduate School / US Food and Drug Administration / University of Nottingham / Stanford University / Clinical Research Organisation / /
Person
Peter Francis / Jingkang Wang Biomics / Geoff Symons Calimmune / John Chiplin / George Dickson / Peter French / David Suhy Benitec / Mel Bridges / Greg West / Greg West Registered / Maria Kavallaris / David Yeomans / York Zhu / Kevin Buchi / Michael Graham Benitec / David Suhy / Ken Reed / Iain Ross / Carl Stubbings / Geoff Symonds / John Rossi / Michael Graham / Anesthesia / / /
Position
Certified Public Accountant / General / Principal Scientific Officer and Manager / Director Number / Chief Scientific Officer / CEO / Professor / President of the Australia / Managing Director / experienced businessman / CDIR Non-Executive Director / Qualified Chartered Director / Corporate Vice President / Global Branded Products / board member / Non-Executive Chairman / legal specialist / Chief Scientist / pain mediator / Director of Pain Research / Non-Executive Director / Director and audit committee Chairman / international leader in pain research / Chief Operating Officer / Chief Financial Officer and Head of Business Development / Vice Chairman / director in the global biotechnology and healthcare industry / Managing Director & CEO / Chief Executive Officer / Chartered Accountant / AUDITOR / President and CEO / Major / Director Appointed / Associate Professor / Contents Corporate Directory CHAIRMAN AND THE CEO / founding CEO / inflammatory mediator / CEO and public company director / FAICD Non-Executive Director / Company Secretary / Chairman / director / CPA Non-Executive Director / synthetic organic chemist / cell and molecular biologist / Past President of the Australia / /
Product
GT308 / Cal -1 therapy using Benitec’s gene silencing platform / Cal-1 / Lucentis / Q4 / Cal -1 / Tribetarna™ / Federal Drug / gene / TT-034 / ddRNAi / /
ProvinceOrState
California / New South Wales / Massachusetts / /
Region
South Wales / /
SportsLeague
Stanford University / /
Technology
ddRNAi‐based gene silencing technology / chemotherapy / Recombinant DNA / biotechnology / preclinical asset using ddRNAi technology / Gene Therapy / Diseases Dividends The ddRNAi technology / broadly using ddRNAi technology / ddRNAi technology / ddRNAi gene silencing technology / Biopharmaceuticals / gene therapy technology / clinical trial protocol / drug development / /
Benitec Biopharma Ltd ABNF6ABarr Street Balmain NSW 2041 Australia Tel: +6986